Amphotericin B Injection Dealers in Mumbai

• Country of Origin: India
• Brand Name: PHOSOME
• Grade: Medicine Grade
• Form: INJECTION
• Shelf Life: 2 Year
• Manufacturer By: Cipla Ltd
• Usage: Fungal Infection Problems
• Composition: Liposomal Amphotericin B (50mg)

Phosome 50mg Injection is an antifungal medication. It is used in the treatment of severe fungal infections and leishmaniasis. It kills fungi by destroying the fungal cell membrane. This way it helps treat the condition.

• Form: Tablets / Liquid / Capsules / Powder
• Packaging Type: Plastic Bottle
• Usage: Clinical, hospital etc.
• CATEGORY: Anti-Fungal Drugs
• Dosage: 5mg
• Grade Standard: Medicine Grade
• Storage: Cool and Dry Place
• Storage: Cool and Dry Place

DESCRIPTION  Amphotericin B Lipid Complex injection 10,25,50 & 100 mg  is used in treatment of invasive fungal infections in patients refractory to conventional amphotericin B therapy.It act by altering fungal cell membrane permeability by binding to the sterol component of the cell membrane. There are many generic manufacturers in India who manufacture  Amphotericin B Lipid Complex injection10,25,50 & 100 mg including United biotech etc. 3s corporation is Supplier,Exporter ,Wholesaler  for  Amphotericin B Lipid Complex injection 10,25,50 & 100 mg in India.   ADDITIONAL INFORMATION For Systemic Fungal Infections in Adults and Children IV dose of  5 mg/kg/day as a single infusion is given. In case of Renal Function Impairment (CrCl less than 10 mL/min)dose of 5 mg/kg every 24 to 36 h is given. SIDE EFFECTS CARDIOVASCULAR Phlebitis (25%); hypertension, tachycardia (23%); hypotension (22%); chest pain (12%); cardiac arrest (6%); vasodilatation (5%); atrial fibrillation, bradycardia, cardiac arrest, cardiomegaly, hemorrhage, postural hypotension, valvular heart disease, vascular disorder (2% to 10%); cardiovascular disorder (at least 5%); CHF, shock, supraventricular tachycardia, syncope, ventricular extrasystoles (1% to less than 5%); MI, shock, tachypnea. CNS Insomnia (22%); headache (21%); anxiety (14%); asthenia, confusion (13%); dizziness (10%); abnormal thinking, agitation, coma, convulsions, depression, dysesthesia, hallucinations, malaise, nervousness, paresthesia, somnolence, tremor (2% to 10%); hypertonia, neuropathy, psychosis, speech disorder, stupor (1% to less than 5%); cerebral vascular accident, diplopia, encephalopathy, extrapyramidal syndrome, peripheral neuropathy, transient vertigo. DERMATOLOGIC Rash (25%); pruritus, sweating (11%); alopecia, dry skin, herpes simplex, maculopapular rash, purpura, skin discoloration, skin disorder, skin ulcer, urticaria, vesiculobullous rash (2% to 10%); acne, petechial rash, skin nodule (1% to less than 5%); erythema, erythema multiforme, exfoliative dermatitis, flushing. EENT Conjunctivitis, dry eyes, eye hemorrhage, pharyngitis (2% to 10%); amblyopia, deafness, ear disorder, tinnitus (1% to less than 5%); visual impairment. GI Vomiting (44%); nausea (40%); diarrhea (30%); abdominal pain (22%); constipation (21%); anorexia (14%); GI hemorrhage, nausea and vomiting (11%); abdomen enlarged, dry mouth/nose, dyspepsia, dysphagia, eructation, fecal incontinence, flatulence, hemorrhoids, gum/oral hemorrhage, hematemesis, ileus, mucositis, rectal disorder, stomatitis, ulcerative stomatitis (2% to 10%); bloody diarrhea, GI disorder, gingivitis, glossitis, increased GGT, melena, mouth ulceration, oral moniliasis, rectal disorder (1% to less than 5%); cramping, epigastric pain. GENITOURINARY Nephrotoxicity (63%); hematuria (14%); kidney failure (5%); abnormal renal function, acute kidney failure, acute renal failure, dysuria, toxic nephropathy, urinary incontinence, vaginal hemorrhage (2% to 10%); albuminuria, glucosuria, oliguria, urinary retention, urinary tract disorder (1% to less than 5%); anuria, azotemia, decreased renal function, hemorrhagic cystitis, hyposthenuria, impotence, nephrocalcinosis, renal tubular acidosis. HEMATOLOGIC-LYMPHATIC Anemia (48%); leukopenia (17%); thrombocytopenia (13%); coagulation disorder, decreased or increased prothrombin, ecchymosis, fluid overload, petechiae (2% to 10%); decreased thromboplastin, hypochromic anemia, increased fibrinogen, leukocytosis (1% to less than 5%); blood dyscrasias including coagulation defects, eosinophilia, normochromic or normocytic anemia; agranulocytosis (postmarketing). HEPATIC Bilirubinemia (19%); increased ALT (15%); abnormal LFTs, increased AST (13%); hepatocellular damage, hepatomegaly, veno-occlusive liver disease (2% to 10%); jaundice (at least 5%); liver failure (1% to less than 5%); cholangitis, cholecystitis, hepatitis. HYPERSENSITIVITY Allergic reaction (2% to 10%); anaphylactic and anaphylactoid reactions, bronchospasm, hypersensitivity pneumonitis, wheezing. LOCAL Injection-site inflammation (2% to 10%); injection-site pain, injection-site reaction (1% to less than 5%); thrombophlebitis. METABOLIC-NUTRITIONAL Hypokalemia (51%); hypomagnesemia, increased creatinine (49%); increased BUN (31%); hyperglycemia (28%); increased alkaline phosphatase (22%); hypocalcemia (21%); peripheral edema (17%); edema, hypervolemia (15%); hyponatremia (12%); hypernatremia (11%); acidosis, hyperchloremia, hyperkalemia, hypermagnesemia, hyperphosphatemia, hypophosphatemia, hypoproteinemia, increased amylase, increased LDH, increased nonprotein nitrogen, respiratory alkalosis (2% to 10%); weight gain (at least 5%); dehydration, hyperlipidemia, hypoglycemia, weight loss (1% to less than 5%); hyperamylasemia, hyperuricemia. MUSCULOSKELETAL Back pain (12%); arthralgia, bone pain, dystonia, myalgia, neck pain, rigors (2% to 10%); myasthenia including bone, joint, and muscle pain. RESPIRATORY Dyspnea (29%); increased cough (22%); hypoxia (21%); epistaxis (20%); lung disorder (18%); pleural effusion (13%); rhinitis (11%); respiratory failure (8%); apnea (at least 5%); hyperventilation (5%); asthma, atelectasis, hemoptysis, hiccup, lung edema, pneumonia, respiratory insufficiency, sinusitis (2% to 10%); respiratory disorder (1% to less than 5%); bronchospasm, cyanosis/hypoventilation, pulmonary edema (postmarketing). MISCELLANEOUS Chills/rigors (90%); chills (77%); fever (58%); blood product transfusion reaction (19%); pain, sepsis (14%); infection (13%); multiple organ failure (11%); procedural complications (10%); cell-mediated immunological reaction, cellulitis, face edema, graft-versus-host disease, influenza-like symptoms (2% to 10%); chills/fever (7%); mucous membrane disorder (at least 5%); death, hypothermia, immune system disorder (1% to less than 5%); angioedema (postmarketing).

• Packaging Type: Vials
• Brand Name: Aesmira
• API Form: Liquid
• Medicine Type: Allopathic
• Treatment: Used to Treat a Variety of Serious Fungal Infections
• Composition: Liposomal Amphotericin B
• Generic Name: Ampocalus B
• Marketed By: Miracalus Pharma Pvt. Ltd.
• Manufactured in India by: Naprod Life Sciences Pvt. Ltd.

• Form: Powder
• Usage: Clinical, Hospital, Personal
• Packaging Type: Vial
• Dose/Strength (ex. 1 mg or 1 ml): 50mg
• Type: Single Dose Vial , Sterile